Lataa...
Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
Further understanding of psoriasis pathogenesis has led to the development of effective biologic medications. Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets the p19 cytokine subunit in IL-23 and IL-39 and is US Food and Drug Administration (FDA) approved for the t...
Tallennettuna:
| Julkaisussa: | Ther Clin Risk Manag |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6110646/ https://ncbi.nlm.nih.gov/pubmed/30174431 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S177127 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|